300110.SZ
Huaren Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 2.80
−2.10%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.3B | 1.3B | 1.4B | 1.6B | 1.6B |
| Cost of Revenue | 845.5M | 831.9M | 876.8M | 937.2M | 918.7M |
| Gross Profit | 482.4M | 489.5M | 476.3M | 699.1M | 700.8M |
| Operating Expenses | |||||
| R&D Expense | 67.4M | 67.8M | 72.3M | 68.7M | 55.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 90.6M | 90.4M | 101.5M | 97.0M | 105.5M |
| Selling & Marketing Expense | 149.6M | 150.4M | 141.7M | 214.0M | 225.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 367.4M | 372.5M | 393.4M | 467.6M | 478.4M |
| Cost and Expenses | 1.2B | 1.2B | 1.3B | 1.4B | 1.4B |
| Operating Income (EBIT) | (450.1M) | (455.7M) | (1.4B) | 225.9M | 198.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (457.1M) | (458.9M) | (1.4B) | 230.5M | 205.9M |
| Income Tax Expense | 2.0M | 447.8K | 7.1M | 37.1M | 24.6M |
| Bottom Line | |||||
| Net Income | (463.0M) | (462.9M) | (1.4B) | 188.1M | 180.8M |
| Earnings from Cont. Ops | (459.1M) | (459.4M) | (1.4B) | 193.4M | 181.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (463.0M) | (462.9M) | (1.4B) | 188.1M | 180.8M |
| Per Share | |||||
| Basic EPS | (CN¥0.39) | (CN¥0.39) | (CN¥1.16) | CN¥0.16 | CN¥0.15 |
| Diluted EPS | (CN¥0.39) | (CN¥0.39) | (CN¥1.16) | CN¥0.16 | CN¥0.15 |
| Revenue Per Share | CN¥1.12 | CN¥1.12 | CN¥1.14 | CN¥1.38 | CN¥1.37 |
| Shares | |||||
| Basic Shares Outstanding | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B |
| Diluted Shares Outstanding | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B |
| Profitability Metrics | |||||
| EBITDA | — | (339.5M) | (1.2B) | 360.4M | 358.1M |
| D&A | — | 116.2M | 126.5M | 134.4M | 159.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026